Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category (Descending) Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00703-5656-91 00703-5656 Etoposide Toposar 20.0 mg/mL Chemotherapy Plant Alkaloid Epipodophyllotoxins Intravenous May 16, 2013 June 30, 2017 No Longer Used
00143-9204-01 00143-9204 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 14, 2021 In Use
00143-9205-01 00143-9205 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Jan. 14, 2021 In Use
00143-9385-01 00143-9385 Decitabine Decitabine 50.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous April 15, 2022 In Use
00955-1020-01 00955-1020 Docetaxel Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 21, 2010 In Use
00955-1021-04 00955-1021 Docetaxel Docetaxel 80.0 mg/4mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 21, 2010 In Use
00955-1022-08 00955-1022 Docetaxel Docetaxel 160.0 mg/8mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 23, 2016 In Use
44087-4000-00 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-04 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-05 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-06 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-07 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-08 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-09 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
48818-0001-01 48818-0001 Pralatrexate Folotyn 20.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 24, 2009 June 30, 2023 No Longer Used
48818-0001-02 48818-0001 Pralatrexate Folotyn 20.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sept. 24, 2009 Feb. 29, 2024 No Longer Used
43598-0865-60 43598-0865 Bortexomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Nov. 1, 2019 In Use
50268-0761-11 50268-0761 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 23, 2017 In Use
50268-0761-12 50268-0761 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 23, 2017 In Use
50268-0762-11 50268-0762 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 23, 2017 In Use
50268-0762-12 50268-0762 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 23, 2017 In Use
50268-0527-15 50268-0527 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral May 26, 2021 In Use
50419-0208-01 50419-0208 Radium Ra 223 dichloride Xofigo 30.0 uCi/mL Chemotherapy Radiopharmaceutical Radium 223 Intravenous May 20, 2013 In Use
50419-0385-01 50419-0385 Copanlisib Aliqopa 15.0 mg/mL Chemotherapy Enzyme Inhibitor PI3K Intravenous Sept. 14, 2017 In Use
50419-0385-72 50419-0385 Copanlisib Aliqopa 15.0 mg/mL Chemotherapy Enzyme Inhibitor PI3K Intravenous Oct. 30, 2018 In Use
51144-0002-12 51144-0002 Tucatinib TUKYSA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral April 17, 2020 In Use
51144-0002-60 51144-0002 Tucatinib TUKYSA 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral April 17, 2020 In Use
50419-0392-01 50419-0392 LAROTRECTINIB VITRAKVI 20.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor TRK OROPHARYNGEAL July 26, 2019 In Use
51144-0001-60 51144-0001 Tucatinib TUKYSA 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor HER2 Oral April 17, 2020 In Use
51991-0797-98 51991-0797 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Subcutaneous Aug. 7, 2017 Jan. 31, 2024 No Longer Used
54879-0027-11 54879-0027 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous May 29, 2019 In Use
55390-0370-10 55390-0370 Topotecan Hydrochloride Topotecan Hydrochloride 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 1, 2020 In Use
59923-0702-02 59923-0702 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 20, 2008 In Use
59923-0702-05 59923-0702 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb. 20, 2008 In Use
59923-0714-02 59923-0714 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous March 1, 2019 In Use
59923-0715-05 59923-0715 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous March 1, 2019 In Use
59923-0716-15 59923-0716 Irinotecan Hydrochloride Irinotecan Hydrochloride 20.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 6, 2019 In Use
59923-0721-60 59923-0721 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 1, 2020 In Use
59923-0722-12 59923-0722 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral March 1, 2020 In Use
61703-0342-09 61703-0342 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 1, 2004 In Use
61703-0342-22 61703-0342 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 1, 2004 In Use
61703-0342-50 61703-0342 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 1, 2004 In Use
64679-0793-01 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0793-02 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0793-03 64679-0793 imatinib mesylate Imatinib Mesylate 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0794-01 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0794-02 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64679-0794-03 64679-0794 imatinib mesylate Imatinib Mesylate 400.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Jan. 17, 2019 In Use
64980-0276-06 64980-0276 Capecitabine Capecitabine 150.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 1, 2017 In Use
64980-0277-12 64980-0277 Capecitabine Capecitabine 500.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Oral Feb. 1, 2017 In Use

Found 10,000 results in 6 milliseconds — Export these results